DERMATOFIBROSARCOMAPROTUBERANS (DFSP): A CASE REPORT OF A COMPLETE CURE

Prajwal Pudasaini¹, Sushil Paudel¹, Sadiksha Adhikari¹, and Monique Kafle²

¹Civil Service Hospital ²Patan Academy of Health Sciences School of Medicine

April 21, 2022

Abstract

DERMATOFIBROSARCOMAPROTUBERANS (DFSP) is a rare recurrent fibrohistiocytic tumor. Given the limitation of available diagnostic modalities in a resource poor setting, diagnosis can be confusing. As most of the tumors recur with time, our case of complete cure was interesting phenomenon observed in our case

DERMATOFIBROSARCOMAPROTUBERANS (DFSP): A CASE REPORT OF A COMPLETE CURE

Key Words : dermatofibrosarcoma protuberans, storiform collagenoma

Word count: 755 figure:3

Prajwal Pudasaini¹, Sushil Paudel¹, Sadiksha Adhikari², Monique Kafle³

¹Registrar, Civil Service Hospital, Kathmandu, Nepal;² Medical Officer, Civil Service Hospital;³Lecturer, Patan Academy of Health Sciences

Correspondence

Prajwal Pudasaini, Department of Dermatology, Civil Service Hospital, Government of Nepal

Email: prajwalpudasaini@gmail.com

Authors:

Dr. Prajwal Pudasaini, Dr. Sushil Paudel, Dr Sadiksha Adhikari, Dr Monique Kafle

Department of Dermatology, Civil Service Hospital, Government of Nepal

Email: prajwalpudasaini@gmail.com Phone no: +9779849447266

Conflict of interest : None

Key clinical message:

DERMATOFIBROSARCOMAPROTUBERANS (DFSP) is a rare recurrent fibrohistiocytic tumor. Because of the rarity of the disease, non-specific presentation and lack of Immunohistochemistry (IHC) its diagnosis is often delayed and prompt treatment is deferred, which can lead to complications such as recurrence and metastasis. Given the limitation of available diagnostic modalities in a resource poor setting, diagnosis can be confusing. As most of the tumors recur with time, our case of complete cure was interesting phenomenon observed in our case.

Acknowledgements:

I would like to express my very great appreciation to Dr Monique Kafle for his valuable and constructive suggestions during the planning and development of this research work. His willingness to give time so generously has been very much appreciated.

I would also like to thank the Department of Pathology of the Civil Service Hospital for their constant support.

Case Report:

BACKGROUND

DermatoFibroSarcomaProtuberans (DFSP) is a rare, slow growing, recurrent tumor arising mostly from the dermis and subcutaneous fat. Patients present with slow growing multinodular solitary growth in trunk with recurrence post treatment.¹ DFSP is a CD34 positive tumor with predominance of spindle cells in the histopathological sections. The etiological association with the COL1A1-PDGFB has led to the dramatic response to the new therapeutic lineage of tyrosine kinase inhibitor- imatinib mesylate.² Given the lack of availability of the FDA approved targeted therapy, imatinib mesylate for recurrent DFSP in resource poor setting like ours, priority should be given towards wide local excision with 2-4cm margin in its treatment. The median age of onset of disease is around 40 years with male predominance.³ The histopathology of DFSP which is the confirmatory test, shows storiform collagenoma with pleomorphism of the spindle cells of the dermis.⁴ The mitotic rate in the spindle cells co-relate with the metastasis, which is rare.⁵ DFSP is difficult for the clinicians to diagnose and treat because of the rarity of the disease, non- specific presentation and high degree of recurrence. Here, we report a rare case report of DFSP with complete cure post wide local excision.

OBSERVATION

A 64-year-old male patient from Kathmandu, retired serviceman presented with asymptomatic to occasionally painful slow growing lesion over upper back, left scapular region for 16 years. Initially, single pinhead sized, firm, raised lesion with red color was noted over left upper back that increased in size and number with largest one showing multinodular appearance and firm consistency. Lesions evolved over period of years with 3 in number and larger plaque progressed to form indurated infiltrated plaque with surrounding redness and prominent overlying solitary papule in the other small plaque. On examination, 3 plaques were noted with the largest plaque 4 * 3 cm in size roughly oval in shape over the left upper back in the scapular region, approx. 5 cm from mid-vertebral line of the spine (Figure 1). Biopsy was done which showed storiform collagenoma of the spindle cells with whorled pattern. Wide local excision with 2-4 cm margin was done along with reconstruction with Z-plasty flaps. (Figure 2) The excision site with reconstruction healed over time with minimal scarring. (Figure 3) There was complete cure of the disease post treatment with no recurrence till date.




Figure 1: Large plaque 4 * 3 cm in size roughly oval in shape over the left upper back in the scapular region



Figure 2: Wide Local Excision of DFSP with flap reconstruction



Figure 3: Healed excision site with minimal scar post treatment

DISCUSSION

DFSP is a recurrent, locally invasive tumor arising mostly from the dermis and subcutaneous fat. Patients mostly present with slow growing multinodular growth in trunk.¹ It's predominantly seen in 20-40 years

of age, in which skin coloured indurated, multinodular solitary plaque is seen over trunk, shoulder and pelvic areas. There's no gender predilection of the disease.⁶ Recurrence is a common rule in DFSP and most of the tumors exhibit recurrence that warrant wide excision with margin.Even after years of treatment, patients can present with lesions suggestive of the disease that need surgery along with reconstruction flaps.⁷ These tumors have locally invasive potential and need recurrent surveillance and follow up visits along with proper counselling.⁸ As DFSP is rare, given the limitation of available diagnostic modalities like Immunohistochemistry (IHC), in a resource- poor setting, diagnosis can be confusing. Diagnosis can be made with good clinical acumen, histopathology and IHC. With proper diagnosis, overall prevalence of the disease can be estimated and clinical therapeutic trials can be performed with timely prevention of fibrosarcomatous transformation in those with potential. DFSP has the potential for recurrence and local invasion of tissues nearby.⁹

Ethical Statement for Clinical Case Reports

Hereby, I Dr Prajwal Pudasaini, MD consciously assure that for the manuscript DERMATOFIBROSAR-COMAPROTUBERANS (DFSP): A CASE REPORT OF A COMPLETE CURE the following is fulfilled:

1) This material is the authors' own original work, which has not been previously published elsewhere.

2) The paper is not currently being considered for publication elsewhere.

3) The paper reflects the authors' own research and analysis in a truthful and complete manner.

4) The paper properly credits the meaningful contributions of co-authors and co-researchers.

5) The results are appropriately placed in the context of prior and existing research.

6) All sources used are properly disclosed (correct citation). Literally copying of text must be indicated as such by using quotation marks and giving proper reference.

7) All authors have been personally and actively involved in substantial work leading to the paper, and will take public responsibility for its content.

The violation of the Ethical Statement rules may result in severe consequences.

To verify originality, my article may be checked by the originality detection software.

I agree with the above statements and declare that this submission follows the policies of Clinical Case Reports as outlined in the Guide for Authors and in the Ethical Statement.

Date: 4/20/2022

Corresponding author's signature: prazol

Consent Statement for Clinical Case Reports

Hereby, I Dr Prajwal Pudasaini, MD consciously assure that for the manuscript DERMATOFIBROSAR-COMAPROTUBERANS (DFSP): A CASE REPORT OF A COMPLETE CURE author has confirmed during submission that patient consent has been signed and collected in accordance with the journal's patient consent policy.

I agree with the above statements and declare that this submission follows the policies of Clinical Case Reports as outlined in the Guide for Authors and in the Ethical Statement.

Date: 4/20/2022

Corresponding author's signature: prazol

Data availability statement

The data that support the findings of this study are openly available in Clinical Case Reports

References:

- 1. Gladdy RA, Wunder JS. Risk-stratified surveillance in dermatofibrosarcoma protuberans: Less is more. Cancer. 2019 Mar 01;125(5):670-672. [PubMed] [Reference list]
- Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. *Genes Chromosomes Cancer*. 2003;37(1):1-19. doi:10.1002/gcc.10202
- 3. Rutgers EJT, Kroon BBR, Albus-Lutter CE, et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1992;18:241–8. [PubMed] [Google Scholar] [Ref list]
- 4. Weiss SW, Goldblum JR, editors. Soft tissue tumors. 4th ed. St Louis: Mosby; 2001. Enginger and Weiss S. [Google Scholar] [Ref list]
- 5. Hayakawa K, Matsumoto S, Ae K, Tanizawa T, Gokita T, Funauchi Y, Motoi N. Risk factors for distant metastasis of dermatofibrosarcoma protuberans. J Orthop Traumatol. 2016 Sep;17(3):261-6. [PMC free article] [PubMed] [Reference list]
- Brooks J, Ramsey ML. Dermatofibrosarcoma Protuberans. [Updated 2022 Jan 21]. In: Stat-Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513305/
- 7. Shah SR, Regmee S, Maharjan DK, Thapa PB. Recurrent Dermatofibrosarcoma Protuberance: A Case Report. JNMA J Nepal Med Assoc . 2021;59(243):1192-1195. Published 2021 Nov 15. doi:10.31729/jnma.7187
- K C, H. B., Shrestha, J. M., & Lohani, I. (2020). Recurrent dermatofibrosarcoma protuberans: A Case report and literature review. *Journal of Society of Surgeons of Nepal*, 23 (2), 67–69. https://doi.org/10.3126/jssn.v23i2.35844
- Ghimire, R., Subedi, S., Sharma, A., & Bohara, S. (2016). Anterior abdominal wall dermatofibrosarcoma protuberans: a case report. *Journal of Society of Surgeons of Nepal*, 17 (1), 39–41. https://doi.org/10.3126/jssn.v17i1.15180





